

Genetic polymorphisms that modulate cardiovascular injury & function

It's your genes Or is it?

Meredith Allen

Consultant Intensive Care

Royal Brompton Hospital, London

&

Critical Care Group, Institute of Child Health, London

m.allen@rbht.nhs.uk

Why look at genes?

**Small variations in genotype can make
big differences to phenotype (1.24%)**



Why look at genes?

- (i) We think we know what biological mediators are playing a role in cardiac dysfunction – *use genetics to confirm this*


Single Nucleotide Polymorphisms

- (ii) We don't really understand what's going on & we want help as to where to look – *use genetics to give us clues*

Genome wide association studies



Using SNP's to help confirm the
important biological mediators



GAAATAATTAATGTTTTGCTTCCTTCTCCTATTTTGTGCTTTACTTCAATTTATTTATTTATTATTAATATTATTATTTTGTG
AGACGGAGTTTCACTCTTGTGTCACCTGAGTGCAGTGGCGTGATCTCAGCTCACTGCACACTCCGCTTTCCTGG
TTTCAAGCGATTCTCCTGCTCAGCCTCCTGAGTAGCTGGGACTACAGTCACACACCCACACGCGCGGCTAATTTTGT
TATTTTASTAGAGTTGGGGTTTCACCATGTTGGCCAGACTGGTCTCGAACTCCTGACCTTGTGATCCGCCAGCCTCT
GCCTCCCAAAGAGCTGGGATTACAGCGCGTGAGCCACCGCGCTCGGCCCTTTGCATCAATTTCTACAGCTTGTTTTCTT
TGCTTGAGCTTTACAAGTCTTACCTTGTCTGCTTCAGATATTTGTGTGGTCTCATCTCTGTGTGCCAGTAGCTAAAA
ATCCATGATTTGCTCTCATCCCACTCCTGTTGTTTCATCTCCTCTTATCTGGGGTCACTCTCTCTCTGATTGCATT
CTGATCCCGAGTACTTAGCATGTGCGTAACAACTCTGCCTCTGCTTTOCCAGGCTCTCTGTGGGGTGGTGTTCATGCC
TCAGAAAAATGCATTGTAAGTTAAATTATTAAGATTTTAAATATAGGAAAAAGTAAGCAAACATAAGGAACAAAA
GGAAAGAACATGTATTCTAATCCATTATTTATTATACAATTAAGAAATTTGGAACTTTAGATTACACTGCTTTTAGAG
ATGGAGATGTAGTAAGTCTTTTACTCTTTACAAAATACATGTGTTAGCAATTTTGGGAAGAATAGTAACTCACCCGAA
CAGTGTAAATGTGAATATGTCACCTTACTAGAGGAAAGAAGGCCACTTGAAAAACATCTCTAAACCGTATAAAAAACAATTA
CATCATAATGATGAAAACCCAAGGAATTTTTTTAGAAAACATTACCAGGGCTAATAACAAAGTAGAGCCCATGTGCAT
TTATCTTCCCTTTGTGTCTGTGTGAGAATTCTAGAGTTATATTTGTACATAGCATGGA AAAATGAGAGGCTAGTTTATC
AACTAGTTCATTTTTAAAAGTCTAACACATCCTAGGTATAGGTGAAGTGTCTCTCTGCCAATGTATTGCACATTTGTGC
CCAGATCCAGCATAGGGTATGTTTGCCATTACAAAGGTTTATGTCTTAAGAGAGGAAATATGAAGAGCAAAACAGT
GCATGCTGGAGAGAGAAAAGCTGATACAAATATAAATGAAACAATAATTGGAAAAATTGAGAACTACTCATTITCTAA
ATTACTCATGTATTTTCTAGAAATTAAGTCTTTTAAATTTTGTATAATCCCAATGTGAGACAAGATAAGTATTAGTGAT
GGTATGAGTAATTAATATCTGTTATATAATATTCATTTTCATAGTGGAAAGAAATAAAATAAAGGTTGTGATGATTGTTG
ATTATTTTTTCTAGAGGGGTTGTCAGGGAAAGAAATTGCTTTTTTTCATTCTCTCTTTCCACTAAGAAAGTTCACTATT
AATTTAGGCACATACAATAATTACTCCATTCTAAAAATGCCAAAAAGGTAATTTAAGAGACTTAAACTGAAAAGTTTA
AGATAGTCACACTGAACTATATTA AAAAATCCACAGGGTGGTTGGAAGTGGGCTTATATTAAAGAGGCTAAAAATTG
CAATAAGACCACAGGCTTTAAATTTGGCTTTAAACTGTGAAAGGTGAACTAGAATGAATAAAATCCTATAAATTTAA
ATCAAAAGAAAGAAACAAA(TA/GA)ATTAAAGTTAATATACAAGAATATGGTGGCCTGGATCTAGTGAACATATAGT
AAAGATAAAACAGAATATTTCTGAAATCCTGGAAAATCTTTTGGGCTAACCTGAAAACAGTATATTTGAAACTATTT
TTAAATGCAAGTGATACTAGAAATATTTTAGAATCATATGTA

Why look at genes?

- unchanged through life
- not altered by disease itself or body's response to the disease
- enable more accurate determination of an individual's risk than a clinical measure (not susceptible to biological fluctuations or measurement error)

If we think we know what biological
processes are involved in cardiac injury /
dysfunction



known gene variant that is associated with
high or low producers




comparing outcomes between genetic
groups



Identify biological processes that are truly
important / worth targeting

Mendelian Randomisation




Mendelian Randomisation

Example

Does cholesterol play a role in coronary artery disease?


Mendelian Randomisation



What do we know?



Gender differences



Lifetime Risk of CHD From Framingham Heart Study




The lifetime risk of developing CHD for 40-year-olds was
1 in 2 for men (RR 48.6% 95% CI 45.8%-51.3%)
and 1 in 3 for women (RR 31.7% 95% CI 29.2%-34.2%)

? Oestrogen Effect

oestrogen →



**Protected
from I/R
injury**





**? cytokine
production
injury**

**? cardiac
dysfunction**



**protected against acute
injury**



Editorials

Gender differences in pediatric cardiac surgery: The surgeon's perspective

Anthony Azakie, MD, CM^a
Isobel A. Russell, MD, PhD, FACC^b

cardiologist's perspective


Wanda C. Miller-Hance, MD^a
Theresa A. Tacy, MD^b

regression analysis demonstrated that female patients had a significantly higher odds ratio for mortality than male patients (odds ratio, 1.51; $P < .01$).

Where do we look?


Under '*extreme stress*' what problems do our patients face?


- LV dysfunction
- endothelial leak
- coagulation disturbances
- nosocomial infection



Wan S et al 1999

Plausible candidate genes






Wan S et al 1999


Cytokine	Biological effects	Hypothesis	Study design	Outcome association
TNF-? (-308 G/A) (TGFB2 allele)	Inflammation Post-pump syndrome, Myocardial dysfunction	Increased risk of MI or CAD	# Pop assoc adult studies >2000	? LV dysfn [OR 3.84] No effect LOS or mortality <i>(Tomasdottir et al 2006)</i> ? ventilation time <i>(Yende et al 2003)</i>
IL-6 (-174 G/C) (-572 G/C)	Inflammation, Myocardial dysfunction	Increased inflammat ⁿ	# Pop assoc adult studies >2000	No assoc with CV risk factors, CV fn, or MI <i>(Lieb W et al 2004)</i> Prolonged hospital stay <i>(Burzotta et al 2001)</i> Risk of postop MI <i>(Podgoreanu et al 2006)</i> Early coronary disease in Tx pts

Cytokine	Biological effects	Hypothesis	Study design	Outcome association
IL-10 (-1082 G/A), (-819 C/T), (-592 A/C)	?-inflammatory suppresses pro- inflammation	Low producers ? pro-inflam ⁿ unchecked	148 Tx donors & recipients	Not assoc with cardiac transplant rejection <i>(Plaza et al 2003, Densem et al 2003, Bijlsma et al 2001)</i>
TGF-β	Endothelium, collagen, profibrotic, ?-inflammatory	Candidate gene for arterial stiffness	>3500 adult population based study	Nil <i>(Sie et al 2007)</i>




Wan S et al 1999

C' component	Biological effects	Hypothesis	Study design	Outcome association
C4 (C4A isotype)	Activated by classic & lectin pathway Null allele ? ? circ levels of C4a & C3a	Increased risk of SIRS	156 paed CPB pts 116 C4A def pts	Homozygous C4A null allele (n=7) ?capillary leak ($p<0.01$) (Zhang S et al 2004) RCT of C4A def children to C4A-rich plasma in CPB prime ? SIRS (biochem & clinical) (Zhang Lancet 2005)
MBL	MBL def assoc with ? infect risk	Infection plays a role in atherosclerosis ? MBL def assoc ?atherosclerosis	434 adults CAD	MBL def haplotype assoc with OR 3.2 [1.5-7] after adjusting for other risk factors (Best et al 2004) Prob co-factor in development of atherosclerosis




Wan S et al 1999

Pattern Recognition Receptors



PRR Receptor	Biological effects	Hypothesis	Study design	Outcome association
CD14	Co-receptor with Toll's for bact products	Inflam ⁿ & infection play a role in atheroma Endothelial & sm muscle cells activated by sol ^b CD14	>3000 adult pts in total	Nil (Unckelbach et al 1999, Zee et al 2001) ? proinflammatory gene expression in plaque (Giacconi et al 2006) ? risk of acute cardiovascular event (Andreotti et al 2002, Arroyo-Espliguero et al 2005)
TLR	Important in innate immune response to pathogens	May mediate inflammation in non-infectious injury	Mice 657 men	Knock-out mouse has ? LV dysfn following I-RP (Favre et al 2007) Toll 4 (-299 A/G) not assoc with atherosclerosis (Hernesniemi et al 2007)
LBP (-326 T/C)	Endotoxin binding protein Polymorphism assoc with variable circ levels & sepsis	endotoxin peaks 4-24hrs post CPB may play a role in myocardial injury	adult	No ? incidence of freq ^y in MI pts (Hubacek et al 2002) may be associated with post CPB morbidity




Wan S et al 1999

Other Polymorphisms

	Biological effects	Hypothesis	Study design	Outcome association
eNOS (-894 G/T)	Constitutively expressed	Exaggerated vasoconstrictive response	105 adult CABG pts	No difference in CI, SVRI, PVRI <i>(Liakopoulos et al 2006)</i>
ACE	ability of mitochondria to fn in anaerobic conditions	Improved outcome in critical illness	2711 healthy males over 15yrs	Currently under debate No clear assoc with CHD Probably a modifier gene <i>(Muthumala et al 2007)</i>
CRP	Pro-inflammatory effect Pro-atherosclerotic	High CRP producers will be pro-atherogenic ? infact size	Mendelian randomisation 4659 men	High producers not assoc ⁿ with risk May be a co-factor <i>(Casas JP et al 2006)</i>

Thus far....

genetic association studies plagued by:
inconsistency
lack of reproducibility
generally small sample sizes



Unfortunately no direct measure of cardiac function

What does predict outcome in our patients?

	Length of Stay (correlation co-efficient [95%CI])	Sepsis (OR [95%CI])	SIRS (in the 1 st 72 hours) (OR [95%CI])
Age	-0.10 [-0.13 - -0.08] <i>p</i> <0.001	0.82 [0.71 – 0.95] <i>p</i> =0.008	1.11 [1.06 – 1.16] <i>p</i> <0.001
Male	0.15 [-0.06 - 0.35] <i>p</i> <0.16	0.86 [0.46 – 1.597] <i>p</i> =0.62	1.27 [0.84 – 1.94] <i>p</i> =0.26
CPB time	0.01 [0.007 - 0.01] <i>p</i> <0.001	1.01 [1.00 – 1.013] <i>P</i> <0.001	1.0 [1.000 – 1.007] <i>P</i> =0.049
X-clamp time	0.01 [0.01 – 0.014] <i>p</i> <0.001	1.01 [1.00 – 1.015] <i>p</i> =0.02	1.0 [0.99 – 1.005] <i>p</i> =0.91
RACHS-1 classification	0.56 [0.48 - 0.65] <i>p</i> <0.001	1.56 [1.22 – 2.01] <i>p</i> <0.001	0.90 [0.74 – 1.11] <i>p</i> =0.33
PIM II score (risk of mortality)	0.04 [0.03 - 0.05] <i>p</i> <0.001	1.00 [0.98 – 1.04] <i>p</i> =0.57	0.97 [0.93 – 1.01] <i>p</i> =0.17
Genetic profile	?	?	?

What does predict outcome in our patients?

	Length of Stay Duration of vent (OR [95%CI])	Sepsis (OR [95%CI])	SIRS (in the 1 st 72 hours) (OR [95%CI])
High TNF-? or IL-6 producers (TNF-?)			

What does predict outcome in our patients?

	Length of Stay (OR [95%CI])	Sepsis (OR [95%CI])	SIRS (in the 1 st 72 hours) (OR [95%CI])
High TNF-? or IL-6 producers (TNF-?)	no effect 0.78 [0.5-1.2] $p=0.16$	no effect 0.63 [0.3-1.3] $p=0.15$	no effect 0.76 [0.4-1.2] $p=0.16$
High TNF-? / Low IL-10 producers (n=109 vs 80)	no effect	no effect	no effect
Complement variants (MBL)	no effect 0.98 [0.66-1.45] $p=0.50$	no effect 1.55 [0.84 – 2.87] $p=0.106$	no effect 0.68 [0.44-1.07] $p=0.06$
PRR haplotype variants (Toll 4)	no effect 0.77 [0.4-1.5] $p=0.26$	no effect 0.78 [0.3-2.3] $p=0.44$	no effect 0.85 [0.4-1.7] $p=0.39$

In the current era of PICU,
genetic effects, whilst inevitably present,
are not detectable

Not useful for bedside risk stratification
at present



'I'm sorry. You've tested positive for the naughty gene.'



Medical practice

Host response to the insult of CPB is too complex to expect any single gene polymorphism to have a significant influence on outcome

practice so
good – no gene
effect

Maybe we are looking at the wrong
genes... or need to look at gene
combinations

Role of genome wide association studies

Genome-wide association studies

High through-put testing involving looking at DNA blocks for variants associated with disease

“pattern recognition”

- requires ‘000’s of pts & controls

Possible now because we have the statistical & bioinformatics infrastructure to support



PRODUCT PIPELINE

FROM GENES TO DRUGS

COMPANY

INVESTORS

SERVICES

Genome-wide association studies

May identify a region of interest but we will still need to understand & apply the biology

Conclusion

- Given complexity of biology – unlikely for single gene SNP to have *signif* effect
- SNP's may play a role in life-time risk models for CV disease
- Need to be aware of the genomic & proteomic research because success will rely on large collaborative projects



'Your genes say 'Man Flu'. But I'm not so sure'